Symbiotec Pharmalab Ltd — earnings calls

Symbiotec Pharmalab reported consolidated revenue of Rs 218 crore for Q1 FY27, up 7% year-on-year, driven largely by its API business which grew 6% with gross margins above 60%. Consolidated EBITDA stood at Rs 45 crore and net profit at about Rs 14 crore, which management said were impacted by operating expenses and depreciation from the new biotech CDMO and complex injectables businesses that have not yet generated revenue. Management reiterated guidance of 20-25% growth in revenue and EBITDA for the fiscal year, with new business revenues expected to begin in the next 6 to 12 months.